AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial to evaluate the tolerability, efficacy, and immune outcomes of
AGEN1884 plus AGEN2034 concurrent with cisplatin and gemcitabine in the neoadjuvant treatment
of muscle-invasive, non-metastatic bladder cancer prior to radical cystectomy.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio